Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ BLPH opened at $0.06 on Tuesday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $11.15. The company has a market capitalization of $673,873.00, a PE ratio of -0.07 and a beta of 0.67. The company has a fifty day moving average of $0.05 and a 200 day moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.